Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Moving beyond cytotoxic drug dosing in ovarian cancer.

Eskander RN, Monk BJ.

Lancet. 2019 Nov 29. pii: S0140-6736(19)32948-4. doi: 10.1016/S0140-6736(19)32948-4. [Epub ahead of print] No abstract available.

PMID:
31791687
2.

Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes.

Gardner AB, Charo LM, Mann AK, Kapp DS, Eskander RN, Chan JK.

Clin Exp Metastasis. 2019 Nov 22. doi: 10.1007/s10585-019-10007-0. [Epub ahead of print]

PMID:
31758289
3.

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.

Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI.

Clin Cancer Res. 2019 Dec 1;25(23):7035-7045. doi: 10.1158/1078-0432.CCR-19-1324. Epub 2019 Aug 4.

PMID:
31383735
4.

Dramatic response to Laetrile and cannabidiol (CBD) oil in a patient with metastatic low grade serous ovarian carcinoma.

Barrie AM, Gushue AC, Eskander RN.

Gynecol Oncol Rep. 2019 May 17;29:10-12. doi: 10.1016/j.gore.2019.05.004. eCollection 2019 Aug.

5.

Opportunistic Salpingectomy at the Time of Urogynecologic Surgery: Why, in Whom, and How?

Catanzarite T, Eskander RN.

Female Pelvic Med Reconstr Surg. 2019 May 22. doi: 10.1097/SPV.0000000000000741. [Epub ahead of print]

PMID:
31135579
6.

Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency.

Eskander RN.

Cancer. 2019 Feb 1;125(3):337-339. doi: 10.1002/cncr.31902. Epub 2018 Dec 18. No abstract available.

PMID:
30561783
7.

The Epigenetic Landscape in the Treatment of Gynecologic Malignancies.

Eskander RN.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:480-487. doi: 10.1200/EDBK_200203. Review.

8.

Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA.

Gynecol Oncol. 2018 Jun;149(3):525-530. doi: 10.1016/j.ygyno.2018.03.043. Epub 2018 Mar 15.

PMID:
29550184
9.

PARP Inhibitors in Epithelial Ovarian Cancer.

Taylor KN, Eskander RN.

Recent Pat Anticancer Drug Discov. 2018;13(2):145-158. doi: 10.2174/1574892813666171204094822. Review.

PMID:
29205122
10.

EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers.

Alldredge JK, Eskander RN.

Gynecol Oncol Res Pract. 2017 Oct 31;4:17. doi: 10.1186/s40661-017-0052-y. eCollection 2017. Review.

11.

Primary low-grade endometrial stromal sarcoma of the omentum.

Clair K, Wolford J, Veran-Taguibao S, Kim G, Eskander RN.

Gynecol Oncol Rep. 2017 Aug 8;21:119-121. doi: 10.1016/j.gore.2017.08.002. eCollection 2017 Aug.

12.

Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report.

Paraghamian SE, Longoria TC, Eskander RN.

Gynecol Oncol Res Pract. 2017 Feb 2;4:3. doi: 10.1186/s40661-017-0038-9. eCollection 2017.

13.

Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24).

Stukan M, Zalewski K, Mardas M, Filarska D, Szajewski M, Kmieć A, Bińkowska P, Pietrzak-Stukan M, Dudziak M, Grabowski JP, Eskander RN, Greimel E.

Eur J Cancer Care (Engl). 2018 Jan;27(1). doi: 10.1111/ecc.12639. Epub 2017 Jan 6.

PMID:
28058740
14.

Erratum to: Immunotherapy in endometrial cancer - an evolving therapeutic paradigm.

Longoria TC, Eskander RN.

Gynecol Oncol Res Pract. 2016 Feb 17;3:2. doi: 10.1186/s40661-016-0021-x. eCollection 2016.

15.

The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients.

Eskander RN, Carpenter BA, Wu HG, Wolf JK.

Curr Med Res Opin. 2016 Jun;32(6):1161-5. doi: 10.1080/03007995.2016.1176014. Epub 2016 Apr 20.

PMID:
27052730
16.

Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.

Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA.

Ann Oncol. 2016 Jan;27(1):114-21. doi: 10.1093/annonc/mdv500. Epub 2015 Oct 20.

17.

Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Eskander RN, Ali S, Dellinger T, Lankes HA, Randall LM, Ramirez NC, Monk BJ, Walker JL, Eisenhauer E, Hoang BH.

Int J Gynecol Cancer. 2016 Jan;26(1):125-32. doi: 10.1097/IGC.0000000000000563.

18.

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.

Tewari KS, Eskander RN, Monk BJ.

Clin Cancer Res. 2015 Sep 1;21(17):3829-35. doi: 10.1158/1078-0432.CCR-15-0088. Epub 2015 Jul 13. Review.

19.

Novel MSH2 Mutation in the First Report of a Vietnamese-American Kindred with Lynch Syndrome.

Eskander RN, Lynch HT, Brown SM, Wagman LD, Tewari KS.

Gynecol Oncol Rep. 2015 Feb 26;12:31-3. doi: 10.1016/j.gore.2015.02.003. eCollection 2015 Apr.

20.

Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer.

Longoria TC, Eskander RN.

Recent Pat Anticancer Drug Discov. 2015;10(2):133-44. Review.

PMID:
25938471
21.

Extensive Tattoos Mimicking Lymphatic Metastasis on Positron Emission Tomography Scan in a Patient With Cervical Cancer.

Grove N, Zheng M, Bristow RE, Eskander RN.

Obstet Gynecol. 2015 Jul;126(1):182-5. doi: 10.1097/AOG.0000000000000701.

PMID:
25923020
22.

Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.

Eskander RN, Tewari KS.

Future Oncol. 2015;11(6):909-22. doi: 10.2217/fon.14.276. Review.

23.

Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.

Eskander RN, Tewari KS.

Clin Ther. 2015 Jan 1;37(1):20-38. doi: 10.1016/j.clinthera.2014.11.010. Review.

24.

Immunotherapy in endometrial cancer - an evolving therapeutic paradigm.

Longoria TC, Eskander RN.

Gynecol Oncol Res Pract. 2015 Dec 2;2:11. doi: 10.1186/s40661-015-0020-3. eCollection 2015. Review. Erratum in: Gynecol Oncol Res Pract. 2016;3:2.

25.

Evaluation of 30-day hospital readmission after surgery for advanced-stage ovarian cancer in a medicare population.

Eskander RN, Chang J, Ziogas A, Anton-Culver H, Bristow RE.

J Clin Oncol. 2014 Dec 20;32(36):4113-9. doi: 10.1200/JCO.2014.56.7743. Epub 2014 Nov 10.

26.

Targeting angiogenesis in advanced cervical cancer.

Eskander RN, Tewari KS.

Ther Adv Med Oncol. 2014 Nov;6(6):280-92. doi: 10.1177/1758834014543794. Review.

27.

Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies.

Eskander RN, Tewari KS.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):847-58. doi: 10.1586/17512433.2014.968554. Epub 2014 Oct 10. Review.

28.

Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer.

Eskander RN, Tewari KS.

J Gynecol Oncol. 2014 Jul;25(3):249-59. doi: 10.3802/jgo.2014.25.3.249. Epub 2014 Jul 3. Review.

29.

PARP inhibition and synthetic lethality in ovarian cancer.

Eskander RN, Tewari KS.

Expert Rev Clin Pharmacol. 2014 Sep;7(5):613-22. doi: 10.1586/17512433.2014.930662. Epub 2014 Jul 2. Review.

30.

Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.

Eskander RN, Tewari KS.

Curr Opin Obstet Gynecol. 2014 Aug;26(4):314-21. doi: 10.1097/GCO.0000000000000042. Review.

PMID:
24979076
31.

Use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A review.

Long B, Eskander RN, Tewari KS.

World J Radiol. 2014 Jun 28;6(6):366-73. doi: 10.4329/wjr.v6.i6.366. Review.

32.

Assessment of palliative care training in gynecologic oncology: a gynecologic oncology fellow research network study.

Eskander RN, Osann K, Dickson E, Holman LL, Rauh-Hain JA, Spoozak L, Wu E, Krill L, Fader AN, Tewari KS.

Gynecol Oncol. 2014 Aug;134(2):379-84. doi: 10.1016/j.ygyno.2014.05.021. Epub 2014 Jun 2.

33.

New paradigms in the surgical and adjuvant treatment of ovarian cancer.

Hodeib M, Eskander RN, Bristow RE.

Minerva Ginecol. 2014 Apr;66(2):179-92. Review.

PMID:
24848076
34.

Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.

Eskander RN, Cripe J, Bristow RE.

Curr Treat Options Oncol. 2014 Mar;15(1):27-40. doi: 10.1007/s11864-013-0264-2. Review.

PMID:
24338278
35.
36.

American Society of Clinical Oncology 2013: summary of scientific advancements in gynecologic cancer.

Eskander RN, Tewari KS.

Int J Gynecol Cancer. 2014 Jan;24(1):13-8. doi: 10.1097/IGC.0000000000000030.

37.

Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.

Eskander RN, Tewari KS.

Clin Pharmacol. 2013 Oct 3;5(Suppl 1):55-61. doi: 10.2147/CPAA.S45885. Review.

38.

Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.

Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B.

Int J Gynecol Cancer. 2013 Jul;23(6):997-1005. doi: 10.1097/IGC.0b013e318296a265.

39.

Outside slide review in gynecologic oncology: impact on patient care and treatment.

Eskander RN, Baruah J, Nayak R, Brueseke T, Ji T, Wardeh R, Tewari KS.

Int J Gynecol Pathol. 2013 May;32(3):293-8. doi: 10.1097/PGP.0b013e31826739c4.

PMID:
23518913
40.

Emerging treatment options for management of malignant ascites in patients with ovarian cancer.

Eskander RN, Tewari KS.

Int J Womens Health. 2012;4:395-404. doi: 10.2147/IJWH.S29467. Epub 2012 Aug 3.

41.

Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.

Dellinger TH, Planutis K, Jandial DD, Eskander RN, Martinez ME, Zi X, Monk BJ, Holcombe RF.

Gynecol Oncol. 2012 Aug;126(2):259-67. doi: 10.1016/j.ygyno.2012.04.026. Epub 2012 Apr 30.

42.

Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line.

Eskander RN, Randall LM, Sakai T, Guo Y, Hoang B, Zi X.

J Obstet Gynaecol Res. 2012 Aug;38(8):1086-94. doi: 10.1111/j.1447-0756.2011.01841.x. Epub 2012 Apr 30.

43.

Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines.

Sakai T, Eskander RN, Guo Y, Kim KJ, Mefford J, Hopkins J, Bhatia NN, Zi X, Hoang BH.

J Orthop Res. 2012 Jul;30(7):1045-50. doi: 10.1002/jor.22050. Epub 2011 Dec 29.

44.

Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy.

Eskander RN, Tarsa M, Herbst KD, Kelly TF.

J Obstet Gynaecol Res. 2011 Nov;37(11):1731-3. doi: 10.1111/j.1447-0756.2011.01591.x. Epub 2011 Jul 25.

PMID:
21790885
45.

A retrospective review of the effect of surgeon specialty on the management of 190 benign and malignant pediatric and adolescent adnexal masses.

Eskander RN, Bristow RE, Saenz NC, Saenz CC.

J Pediatr Adolesc Gynecol. 2011 Oct;24(5):282-5. doi: 10.1016/j.jpag.2011.03.012. Epub 2011 May 19.

PMID:
21600810
46.

Fertility preserving options in patients with gynecologic malignancies.

Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE.

Am J Obstet Gynecol. 2011 Aug;205(2):103-10. doi: 10.1016/j.ajog.2011.01.025. Epub 2011 Mar 16. Review.

47.

Bevacizumab in the treatment of ovarian cancer.

Eskander RN, Randall LM.

Biologics. 2011;5:1-5. doi: 10.2147/BTT.S13071. Epub 2011 Jan 11.

48.

Comparison of computed tomography and magnetic resonance imaging in cervical cancer brachytherapy target and normal tissue contouring.

Eskander RN, Scanderbeg D, Saenz CC, Brown M, Yashar C.

Int J Gynecol Cancer. 2010 Jan;20(1):47-53. doi: 10.1111/IGC.0b013e3181c4a627.

PMID:
20130502

Supplemental Content

Loading ...
Support Center